EMA recommends approval of BioMarin production plant
The two Novato facilities are said to support up to $1bn in revenue for BioMarin’s growing enzyme replacement therapy portfolio. BioMarin CEO Jean-Jacques Bienaime said the company is
Samsung Biologics is set to acquire PolyPeptide Group through an all-cash public tender offer valued at SFr1.46bn ($1.81bn).